Pliant Therapeutics Inc (NASDAQ: PLRX) on Monday, soared 12.39% from the previous trading day, before settling in for the closing price of $13.80. Within the past 52 weeks, PLRX’s price has moved between $10.22 and $19.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -32.88% annually for the last half of the decade. The company achieved an average annual earnings per share of -32.31%. With a float of $53.75 million, this company’s outstanding shares have now reached $60.85 million.
In an organization with 158 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 66.96%, operating margin of -4588.47%, and the pretax margin is -4166.96%.
Pliant Therapeutics Inc (PLRX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Pliant Therapeutics Inc is 11.67%, while institutional ownership is 96.17%. The most recent insider transaction that took place on Jul 10 ’24, was worth 142,408. In this transaction Chief Medical Officer of this company sold 12,319 shares at a rate of $11.56, taking the stock ownership to the 213,052 shares. Before that another transaction happened on Jul 10 ’24, when Company’s Chief Business Officer sold 9,900 for $11.56, making the entire transaction worth $114,444. This insider now owns 227,494 shares in total.
Pliant Therapeutics Inc (PLRX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.69 earnings per share (EPS) for the period topping the consensus outlook (set at -0.82) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.96 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -32.31% per share during the next fiscal year.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Pliant Therapeutics Inc (PLRX) is currently performing well based on its current performance indicators. A quick ratio of 10.26 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.34, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -4.02 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.48 million. That was better than the volume of 0.46 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 87.11%. Additionally, its Average True Range was 0.88.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 89.97%, which indicates a significant decrease from 92.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.39% in the past 14 days, which was higher than the 58.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.27, while its 200-day Moving Average is $13.29. However, in the short run, Pliant Therapeutics Inc’s stock first resistance to watch stands at $16.24. Second resistance stands at $16.97. The third major resistance level sits at $18.14. If the price goes on to break the first support level at $14.34, it is likely to go to the next support level at $13.17. Assuming the price breaks the second support level, the third support level stands at $12.44.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
Market capitalization of the company is 943.84 million based on 60,854K outstanding shares. Right now, sales total 1,580 K and income totals -161,340 K. The company made 0 K in profit during its latest quarter, and -57,760 K in sales during its previous quarter.
